Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis

Ga Young Song; Sung Hoon Jung; Je Jung Lee; Jin Seok Kim; Chang Ki Min; Kihyun Kim; Yunsuk Choi; Hyeon Seok Eom; Young Don Joo; Sung Hyun Kim; Jae Yong Kwak; Hye Jin Kang; Jae Hoon Lee; Ho Sup Lee; Yeung Chul Mun; Joon Ho Moon; Sang Kyun Sohn; Seong Kyu Park; Yong Park; Ho Jin Shin; Sung Soo Yoon

doi:10.1080/10428194.2020.1783448

Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis

Ga Young Song, Sung Hoon Jung, Je Jung Lee, Jin Seok Kim, Chang Ki Min, Kihyun Kim, Yunsuk Choi, Hyeon Seok Eom, Young Don Joo, Sung Hyun Kim, Jae Yong Kwak, Hye Jin Kang, Jae Hoon Lee, Ho Sup Lee, Yeung Chul Mun, Joon Ho Moon, Sang Kyun Sohn, Seong Kyu Park, Yong Park, Ho Jin ShinSung Soo Yoon

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

We compared the efficacy and toxicity of busulfan and melphalan (BUMEL) and those of high-dose melphalan (HDMEL) as conditioning regimens for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) through a propensity score-matched analysis. No significant difference in the complete response and overall response rate after ASCT was observed between BUMEL and HDMEL. After a median follow-up of 37.3 months in the BUMEL group and 50.8 months in the HDMEL group, the median progression-free survival was calculated to be 32.9 months and 25.2 months (p = 0.995). With respect to non-hematologic toxicities, infections were more frequently reported in the BUMEL group (p < 0.001). Three patients who received BUMEL developed veno-occlusive disease (VOD), and all of them recovered without administration of defibrotide. In conclusion, BUMEL is an effective alternative conditioning regimen in terms of efficacy, but attention should be paid to toxicities.

Original language	English
Pages (from-to)	2714-2721
Number of pages	8
Journal	Leukemia and Lymphoma
Volume	61
Issue number	11
DOIs	https://doi.org/10.1080/10428194.2020.1783448
State	Published - Nov 2020

Bibliographical note

Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.

Keywords

Multiple myeloma
autologous stem cell transplantation
conditioning regimen

Access to Document

10.1080/10428194.2020.1783448

Fingerprint

Dive into the research topics of 'Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis'. Together they form a unique fingerprint.

Cite this

Song, G. Y., Jung, S. H., Lee, J. J., Kim, J. S., Min, C. K., Kim, K., Choi, Y., Eom, H. S., Joo, Y. D., Kim, S. H., Kwak, J. Y., Kang, H. J., Lee, J. H., Lee, H. S., Mun, Y. C., Moon, J. H., Sohn, S. K., Park, S. K., Park, Y., ... Yoon, S. S. (2020). Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. Leukemia and Lymphoma, 61(11), 2714-2721. https://doi.org/10.1080/10428194.2020.1783448

@article{d9d474f98fc440038d997875408b0c1f,

title = "Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis",

abstract = "We compared the efficacy and toxicity of busulfan and melphalan (BUMEL) and those of high-dose melphalan (HDMEL) as conditioning regimens for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) through a propensity score-matched analysis. No significant difference in the complete response and overall response rate after ASCT was observed between BUMEL and HDMEL. After a median follow-up of 37.3 months in the BUMEL group and 50.8 months in the HDMEL group, the median progression-free survival was calculated to be 32.9 months and 25.2 months (p = 0.995). With respect to non-hematologic toxicities, infections were more frequently reported in the BUMEL group (p < 0.001). Three patients who received BUMEL developed veno-occlusive disease (VOD), and all of them recovered without administration of defibrotide. In conclusion, BUMEL is an effective alternative conditioning regimen in terms of efficacy, but attention should be paid to toxicities.",

keywords = "Multiple myeloma, autologous stem cell transplantation, conditioning regimen",

author = "Song, {Ga Young} and Jung, {Sung Hoon} and Lee, {Je Jung} and Kim, {Jin Seok} and Min, {Chang Ki} and Kihyun Kim and Yunsuk Choi and Eom, {Hyeon Seok} and Joo, {Young Don} and Kim, {Sung Hyun} and Kwak, {Jae Yong} and Kang, {Hye Jin} and Lee, {Jae Hoon} and Lee, {Ho Sup} and Mun, {Yeung Chul} and Moon, {Joon Ho} and Sohn, {Sang Kyun} and Park, {Seong Kyu} and Yong Park and Shin, {Ho Jin} and Yoon, {Sung Soo}",

note = "Publisher Copyright: {\textcopyright} 2020 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2020",

month = nov,

doi = "10.1080/10428194.2020.1783448",

language = "English",

volume = "61",

pages = "2714--2721",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "11",

}

Song, GY, Jung, SH, Lee, JJ, Kim, JS, Min, CK, Kim, K, Choi, Y, Eom, HS, Joo, YD, Kim, SH, Kwak, JY, Kang, HJ, Lee, JH, Lee, HS, Mun, YC, Moon, JH, Sohn, SK, Park, SK, Park, Y, Shin, HJ & Yoon, SS 2020, 'Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis', Leukemia and Lymphoma, vol. 61, no. 11, pp. 2714-2721. https://doi.org/10.1080/10428194.2020.1783448

Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. / Song, Ga Young; Jung, Sung Hoon; Lee, Je Jung et al.
In: Leukemia and Lymphoma, Vol. 61, No. 11, 11.2020, p. 2714-2721.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma

T2 - a propensity score-matched analysis

AU - Song, Ga Young

AU - Jung, Sung Hoon

AU - Lee, Je Jung

AU - Kim, Jin Seok

AU - Min, Chang Ki

AU - Kim, Kihyun

AU - Choi, Yunsuk

AU - Eom, Hyeon Seok

AU - Joo, Young Don

AU - Kim, Sung Hyun

AU - Kwak, Jae Yong

AU - Kang, Hye Jin

AU - Lee, Jae Hoon

AU - Lee, Ho Sup

AU - Mun, Yeung Chul

AU - Moon, Joon Ho

AU - Sohn, Sang Kyun

AU - Park, Seong Kyu

AU - Park, Yong

AU - Shin, Ho Jin

AU - Yoon, Sung Soo

PY - 2020/11

Y1 - 2020/11

N2 - We compared the efficacy and toxicity of busulfan and melphalan (BUMEL) and those of high-dose melphalan (HDMEL) as conditioning regimens for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) through a propensity score-matched analysis. No significant difference in the complete response and overall response rate after ASCT was observed between BUMEL and HDMEL. After a median follow-up of 37.3 months in the BUMEL group and 50.8 months in the HDMEL group, the median progression-free survival was calculated to be 32.9 months and 25.2 months (p = 0.995). With respect to non-hematologic toxicities, infections were more frequently reported in the BUMEL group (p < 0.001). Three patients who received BUMEL developed veno-occlusive disease (VOD), and all of them recovered without administration of defibrotide. In conclusion, BUMEL is an effective alternative conditioning regimen in terms of efficacy, but attention should be paid to toxicities.

AB - We compared the efficacy and toxicity of busulfan and melphalan (BUMEL) and those of high-dose melphalan (HDMEL) as conditioning regimens for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) through a propensity score-matched analysis. No significant difference in the complete response and overall response rate after ASCT was observed between BUMEL and HDMEL. After a median follow-up of 37.3 months in the BUMEL group and 50.8 months in the HDMEL group, the median progression-free survival was calculated to be 32.9 months and 25.2 months (p = 0.995). With respect to non-hematologic toxicities, infections were more frequently reported in the BUMEL group (p < 0.001). Three patients who received BUMEL developed veno-occlusive disease (VOD), and all of them recovered without administration of defibrotide. In conclusion, BUMEL is an effective alternative conditioning regimen in terms of efficacy, but attention should be paid to toxicities.

KW - Multiple myeloma

KW - autologous stem cell transplantation

KW - conditioning regimen

UR - http://www.scopus.com/inward/record.url?scp=85087449806&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1783448

DO - 10.1080/10428194.2020.1783448

M3 - Article

C2 - 32580672

AN - SCOPUS:85087449806

SN - 1042-8194

VL - 61

SP - 2714

EP - 2721

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 11

ER -